Monia Marchetti

Summary

Affiliation: University of Pavia
Country: Italy

Publications

  1. ncbi Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service
    Monia Marchetti
    Laboratory of Medical Informatics, Institute for Scientific Research and Health Care, Pavia, Italy
    Clin Ther 26:1546-61. 2004
  2. ncbi Clinical and economic impact of epoetins in cancer care
    Monia Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico San Matteo, Pavia, Italy
    Pharmacoeconomics 22:1029-45. 2004
  3. ncbi Cost-effectiveness of universal pneumococcal vaccination for infants in Italy
    M Marchetti
    Laboratory of Medical Epidemiology, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Vaccine 23:4565-76. 2005
  4. ncbi Drug-eluting stents: from evidence to policy
    Monia Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Expert Rev Med Devices 1:49-63. 2004
  5. ncbi Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A
    M Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, and Department of Computer Science and Systems, University of Pavia, Pavia, Italy
    QJM 94:365-72. 2001
  6. ncbi Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis
    M Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Pavia, Italy
    Thromb Haemost 84:752-7. 2000
  7. ncbi Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery
    M Marchetti
    Laboratory of Medical Informatics, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
    Transfusion 40:673-81. 2000
  8. doi Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematol
    Pier Luigi Zinzani
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo Foundation, Viale Golgi 19, 27100, Pavia, Italy
    Haematologica 93:1364-71. 2008
  9. ncbi Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
    Giovanni Barosi
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 91:96-103. 2006
  10. doi SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma
    Giovanni Barosi
    Laboratory of Clinical Epidemiology and Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Ann Hematol 91:875-88. 2012

Detail Information

Publications37

  1. ncbi Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service
    Monia Marchetti
    Laboratory of Medical Informatics, Institute for Scientific Research and Health Care, Pavia, Italy
    Clin Ther 26:1546-61. 2004
    ..Third-generation aromatase inhibitors are effective alternatives to tamoxifen in patients with advanced breast cancer. However, their acquisition costs might burden fixed-budget health care systems...
  2. ncbi Clinical and economic impact of epoetins in cancer care
    Monia Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico San Matteo, Pavia, Italy
    Pharmacoeconomics 22:1029-45. 2004
    ..In the near future we expect that a wider range of epoetins, drug patent expiry, a more appropriate patient selection criteria and an improved dosage schedule may help increase the efficiency of cancer-related anaemia management...
  3. ncbi Cost-effectiveness of universal pneumococcal vaccination for infants in Italy
    M Marchetti
    Laboratory of Medical Epidemiology, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Vaccine 23:4565-76. 2005
    ....
  4. ncbi Drug-eluting stents: from evidence to policy
    Monia Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Expert Rev Med Devices 1:49-63. 2004
    ..However, adequate guidelines and reimbursement strategies are still awaited in several countries...
  5. ncbi Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A
    M Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, and Department of Computer Science and Systems, University of Pavia, Pavia, Italy
    QJM 94:365-72. 2001
    ..Screening for factor V Leiden and prothrombin G20210A, with prolonged prophylaxis of double carriers, is cost-effective in most patients with VTE...
  6. ncbi Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis
    M Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Pavia, Italy
    Thromb Haemost 84:752-7. 2000
    ..34% per year or recurrent DVT at a rate lower than 9% in the first 2 years. The screening policy was cost-saving if restricted to patients with idiopathic DVT and compliant to warfarin therapy...
  7. ncbi Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery
    M Marchetti
    Laboratory of Medical Informatics, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
    Transfusion 40:673-81. 2000
    ..Recombinant human erythropoietin (epoetin) has the potential to decrease perioperative need for allogeneic blood during CABG, but its high cost calls for a careful economic evaluation before it can be recommended for widespread use...
  8. doi Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematol
    Pier Luigi Zinzani
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo Foundation, Viale Golgi 19, 27100, Pavia, Italy
    Haematologica 93:1364-71. 2008
    ....
  9. ncbi Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
    Giovanni Barosi
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 91:96-103. 2006
    ..Recommendations on stem cell transplantation and on which therapy to adopt for refractory or relapsed patients were also formulated...
  10. doi SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma
    Giovanni Barosi
    Laboratory of Clinical Epidemiology and Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Ann Hematol 91:875-88. 2012
    ..In patients who are refractory or relapsing after first-line therapy, we recommended bortezomib and pegylated liposomal doxorubicin, or lenalidomide and dexamethasone combinations (weak positive)...
  11. ncbi The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia
    Vittorio Rosti
    Transplant Research Area, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Blood Cells Mol Dis 38:280-6. 2007
    ..We studied the expression of the chemokine receptor CXCR4 on circulating CD34+ cells of patients with myelofibrosis with myeloid metaplasia (MMM), and examined its relationship to the severity of disease...
  12. ncbi JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
    Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Policlinico S Matteo Foundation, Pavia, Italy
    Blood 110:4030-6. 2007
    ..We conclude that JAK2 V617F genotype should be considered in any future risk stratification of patients with PMF...
  13. ncbi Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies
    Giovanni Barosi
    Laboratorio di Informatica Medica, IRCCS Policlinico S Matteo, 27100 Pavia, Italy
    Leuk Lymphoma 43:2301-7. 2002
    ..The potential for myeloproliferative reactions and the unfavorable dose-related toxicity profile argue for future studies using lower doses of this drug...
  14. ncbi Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
    Nicola Lucio Liberato
    Azienda Ospedaliera della Provincia di Pavia, Divisione di Medicina Interna, Ospedale Civile, Casorate Primo, Pavia, Italy
    J Clin Oncol 25:625-33. 2007
    ..To evaluate the cost-effectiveness of 12-month adjuvant trastuzumab therapy in women with high-risk human epidermal growth factor receptor 2 (HER2) -positive early breast cancer...
  15. ncbi Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 90:1236-57. 2005
    ..By using a systematic literature review and an explicit approach to consensus among experts, recommendations for the key therapeutic decisions in patients with nodal indolent NHL are provided...
  16. ncbi Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis
    M Marchetti
    Laboratory of Medical Informatics, IRCCS Policlinico S. Matteo, Pavia, Italy
    Am J Med 111:130-9. 2001
    ..The apparent increase in recurrence after interruption of therapy needs to be investigated more thoroughly before low-molecular-weight heparin can be recommended routinely...
  17. ncbi Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO)
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 89:717-41. 2004
    ....
  18. ncbi Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial
    Monia Marchetti
    Laboratory of Medical Informatics, Unit of Clinical Immunology and Immunohematology, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy
    J Clin Oncol 22:424-31. 2004
    ..A phase II dose-escalation trial was conducted to ascertain low-dose thalidomide safety and response in patients with advanced myelofibrosis with myeloid metaplasia (MMM)...
  19. ncbi Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Blood 106:2849-53. 2005
    ..A histologic response was defined by changes in bone marrow fibrosis and cellularity grades. The combined use of these response definitions should help standardize the design and reporting of future clinical studies in MMM...
  20. pmc Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
    Ercole Brusamolino
    Clinica Ematologica, Fondazione IRCCS Policlinico San Matteo, Universita di Pavia, Pavia 27100, Italy
    Haematologica 94:550-65. 2009
    ..All fertile patients should be informed of the possible effects of therapy on gonadal function and fertility preservation measures should be taken before the initiation of therapy...
  21. ncbi High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy
    Giovanni Barosi
    Laboratorio di Informatica Medica, IRCCS Policlinico S Matteo, p le Golgi 3, 27100 Pavia, Italy
    Haematologica 87:472-8. 2002
    ..In Italy, typical HFE mutations account for only 64% of the cases with overt hereditary hemochromatosis (HH), and a common HFE-unrelated disease was hypothesized...
  22. ncbi Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia
    G Barosi
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Pavia, Italy
    Br J Haematol 114:78-83. 2001
    ..The unexpected observation of leucocytosis and thrombocytosis suggests biological studies and better criteria for selection of patients for treatment...
  23. ncbi Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia
    G Barosi
    Laboratory of Medical Informatics, the Unit of Clinical Immunology and Immunohematology, The Transfusion Service, Policlinico San Matteo, Pavia, Italy
    Blood 98:3249-55. 2001
    ..In conclusion, the absolute number of CD34(+) circulating cells allows MMM to be distinguished from other Ph(-) CMDs; it is strongly associated with the extent of myeloproliferation and predicts evolution toward blast transformation...
  24. ncbi Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia
    Giovanni Barosi
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Br J Haematol 124:618-25. 2004
    ..These results document that neoangiogenesis is an integral component of spleen re-localization of haematopoietic stem cells and suggest a cellular mechanism for spleen neoangiogenesis...
  25. pmc Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia
    G Barosi
    Laboratory of Medical Informatics, IRCCS Policlinico S Matteo, Pavia, Italy
    Br J Cancer 78:781-7. 1998
    ..More tailored utilization of the drug and better consideration of predictive response indicators may lead to an effective, blood-sparing alternative...
  26. doi Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Tra
    Luca Pierelli
    Servizio di Immunoematologia e Medicina Trasfusionale, A O San Camillo Forlanini, Roma, Italy Università La Sapienza, Roma, Italy Servizio Trasfusionale, UOS Aferesi e nuove tecnologie trasfusionali, A O San Gerardo, Monza, Italy Unità di Ematologia, Divisione di Medicina Interna, Ospedale C Massaia, Asti, Italy Clinica di Oncoematologia Pediatrica, Universita di Padova, Padova, Italy Servizio di Immunoematologia e Trasfusionale, Unità di Terapia Cellulare, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy UO Immunoematologia, A O Universitaria Pisana, Pisa, Italy Divisione Ematologia e Trapianto di Midollo Osseo, Ospedale San Martino, Genova, Italy Dipartimento of Oncologia Ematologia Pediatrica, IRCCS Ospedale Pediatrico Bambino Gesù, Pavia, Italy Università di Pavia, Pavia, Italy Centro Trasfusionale, Ospedale San Martino, Genova, Italy UO Ematologia, A O Careggi and Università di Firenze, Firenze, Italy
    Transfusion 53:2340-52. 2013
    ..Consensus-based recommendations ameliorate the appropriateness in daily clinical practice and, in turn, optimize the use of health care resources...
  27. ncbi Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age
    Monia Marchetti
    Laboratory Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia, Italy
    Hum Vaccin 3:14-22. 2007
    ..Administration of a adjuvanted influenza vaccine to children aged 6 to 60 months was highly cost-effective for the health care service and cost saving for the society...
  28. ncbi Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology
    Emilio Paolo Alessandrino
    Divisione di Ematologia, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 87:1286-306. 2002
    ..The Italian Society of Hematology commissioned a project to develop guidelines for the therapy of MDS using evidence-based knowledge and consensus-formation techniques...
  29. doi Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Carla Rognoni
    Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy
    Clin Drug Investig 34:9-17. 2014
    ..The aim of this study was to estimate the cost effectiveness of NOAs in an Italian setting...
  30. ncbi Deciding when to intervene: a Markov decision process approach
    P Magni
    Dipartimento di Informatica e Sistemistica, Universita degli Studi di Pavia, Via Ferrata 1, I 27100, Pavia, Italy
    Int J Med Inform 60:237-53. 2000
    ..The calculations are carried out with DT-Planner, a graphical decision aid specifically built for dealing with dynamic decision processes...
  31. ncbi Screening for factor V Leiden mutation in pregnant women
    Monia Marchetti
    Lancet 360:1518. 2002
  32. doi Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders
    Emanuele Angelucci
    Hematology Department and BMT Unit, Cancer Center Armando Businco, viale Edward Jenner, 09121 Cagliari, Italy
    Haematologica 93:741-52. 2008
    ....
  33. ncbi Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates
    Nicola Lucio Liberato
    Division of Internal Medicine, Civil Hospital, Voghera, Italy
    Drugs Aging 20:631-42. 2003
    ..Probably, country- and drug-specific policies might increase the efficiency of this treatment. Further outcomes research is required to assess these agents more fully...
  34. ncbi Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
    Tiziano Barbui
    Divisione di Ematologia Spedali Riuniti, Bergamo, Italy
    Haematologica 89:215-32. 2004
    ....
  35. ncbi Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
    Maura Brugiatelli
    Divisione di Ematologia, Azienda Ospedaliera Papardo, Messina, Italy
    Haematologica 91:1662-73. 2006
    ..The Italian Society of Hematology (SIE) and two affiliate societies (SIES and GITMO) commissioned a project to develop clinical practice guidelines for the treatment of chronic lymphocytic leukemia (CLL)...
  36. ncbi What reimbursement for coronary revascularization with drug-eluting stents?
    Rosanna Tarricone
    CeRGAS SDA Bocconi University, Milan, Italy
    Eur J Health Econ 5:309-16. 2004
    ..SES is thus a cost-saving strategy in the perspective of the SSN that could therefore support the introduction of the new technology by reimbursing about 80% of its current incremental acquisition cost...
  37. ncbi Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia
    Margherita Massa
    Laboratory of Biotechnology, Italy
    J Clin Oncol 23:5688-95. 2005
    ..We measured the number of circulating EPCs in patients with myelofibrosis with myeloid metaplasia (MMM), and we examined the relationship between the number of EPCs and severity of the MMM disease process...